SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.

Facit exited McMaster University's cancer radiotherapy spinout in an upsized initial public offering after $158m in funding.

University of Kent's UltraSoc Technologies, which provides integrated circuit safety technologies, has agreed to an acquisition by Siemens.

The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.

Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.

Mastercard will buy financial data technology provider Finicity in a deal that could reach $985m, giving Experian an exit. This is yet another large exits in this space this year after the acquisitions of Plaid and Credit Karma earlier.

Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.

The UCL and Ludwig Institute-linked cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

The SIG-backed video communication software provider priced its shares above the range and will go public later today.

SoftBank Vision Fund owns more than 40% of the precision cancer drug developer, which raised $400m approximately 18 months ago.